Assistant Professor, Medicine - Oncology, Stanford University Medical Center
Oncology
Dr. Joel W. Neal, MD
|
|
Give Review
Joel Neal works in the field of Oncology. He studied medicine at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19 in research and 29 in primary care medicine He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Joel Neal is a published doctor. He published 29 publications, including: 'Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.'
Publications
- Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
- Rapid Onset of Retinal Toxicity from High-Dose Hydroxychloroquine Given for Cancer Therapy.
- GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.
- Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
- Developing biomarker-specific end points in lung Cancer clinical trials.
- Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
- Decade in review-targeted therapy: Successes, toxicities and challenges in solid tumours.
- Review of the current targeted therapies for non-small-cell lung Cancer.
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
- Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung Cancer patients.
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non...
- A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors.
- Isolation and mutational analysis of circulating tumor cells from lung Cancer patients with magnetic sifters and biochips.
- A patient with anaplastic lymphoma kinase-positive non-small cell lung Cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizot...
- A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision with Treatment including Pemetrexed and Bevaci...
- Aflibercept in lung Cancer.
- Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung Cancer.
- Current management of small cell lung Cancer.
- Targeting FGFR, Ephrins, Mer, MET, and PDGFR-? in Non-small Cell Lung Cancer.
- Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC.
- One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung Cancer.
- Cetuximab monotherapy in patients with advanced non-small cell lung Cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
- Exciting new targets in lung Cancer therapy: ALK, IGF-1R, HDAC, and Hh.
- First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
- Histology matters: individualizing treatment in non-small cell lung Cancer.
- InDuction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells.
- A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts.
- Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 Cells.
Schools
Northwestern University The Feinberg School Of Medicine
Beth Israel Deaconess Med Center
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Brigham and Women's Hospital -
Beth Israel Deaconess Medical Center -
Northwestern University Feinberg School of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1790858942 | |
| NPPES Provider LastName | NEAL | |
| NPPES Provider FirstName | JOEL | |
| NPPES Provider ZIPCode | 94305 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 543.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 21.0 | |
| Percent Opioid Claims | 3.87 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790858942 |
| Last Name Of The Provider | NEAL |
| First Name Of The Provider | JOEL |
| View All |
Similar Doctors
|
|
Dr. Joshua Brody, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melinda L. Telli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anosheh Afghahi, MD |
|
|
Dr. Paula Kushlan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Z. Koontz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Millie S. Das, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arash Alizadeh, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michaela Liedtke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Lee, MD |
|
|
Dr. Richard Miller, MD |
|
|
Dr. Priya Chakravarthi, MD |
|
|
Dr. Alice C. Fan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank E. Stockdale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory K. Behbehani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl D. Cho-Phan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily E. Johnston, MD |
|
|
Dr. Anthony P. Lam, MD |
|
|
Dr. Beverly S. Mitchell, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|